

1

2 **Abstract**

3 **Background** The current COVID-19 pandemic has overloaded the diagnostic capacity of laboratories by
4 the gold standard method rRT-PCR. This disease has a high spread rate and almost a quarter of infected
5 individuals never develop symptoms. In this scenario, active surveillance is crucial to stop the virus
6 propagation.

7 **Methods** Between July 2020 and April 2021, 11580 oropharyngeal swab samples collected in closed and
8 semi-closed institutions were processed for SARS-CoV-2 detection in pools, implementing this strategy
9 for the first time in Córdoba, Argentina. Five-sample pools were constituted before nucleic acid
10 extraction and amplification by rRT-PCR. Comparative analysis of cycle threshold (Ct) values from
11 positive pools and individual samples along with a cost-benefit report of the whole performance of the
12 results was performed.

13 **Results** From 2314 5-sample pools tested, 158 were classified as positive (6.8%), 2024 as negative
14 (87.5%), and 132 were categorized as indeterminate (5.7%). The Ct value shift due to sample dilution
15 showed an increase in Ct of 2.6 ± 1.53 cycles for N gene and 2.6 ± 1.78 for ORF1ab gene. Overall, 290 pools
16 were disassembled and 1450 swabs were analyzed individually. This strategy allowed correctly
17 identifying 99.8% of the samples as positive (7.6%) or negative (92.2%), avoiding the execution of 7,806
18 rRT-PCR reactions which represents a cost saving of 67.5%.

19 **Conclusion** This study demonstrates the feasibility of pooling samples to increase the number of tests
20 performed, helping to maximize molecular diagnostic resources and reducing the work overload of
21 specialized personnel during active surveillance of the COVID-19 pandemic.

22 **Keywords:** SARS-CoV-2, pools, surveillance, pooling, COVID19

23 **1. Introduction**

24 The emergence of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
25 coronavirus 2 (SARS-CoV-2) led humanity to an unprecedented pandemic with severe health
26 consequences for the population worldwide. Diagnostic tests are essential due to their ability to detect
27 and provide answers for pandemic management. However, they may be hampered because of the high
28 demand that overwhelmed the healthcare system and the limited supply of reagents required for the
29 setup of these tests. This aspect has been particularly worse in some geographic regions of the world, in
30 low and middle-income countries as well. Thus, the context of SARS-CoV-2 pandemics motivated the
31 design of alternative diagnostic strategies.

32 SARS-CoV-2 infection is characterized by the great diversity of signs and symptoms affecting patients.
33 The most frequently associated with COVID-19 are fever, dry cough and generalized weakness though
34 symptoms such as nausea, diarrhea, loss of smell, pharyngitis and enlarged tonsils have also been
35 reported,[1]. However, about a quarter of infected people never develop symptoms (asymptomatic) and
36 about half of the infected individuals do not manifest any symptom at the testing time
37 (presymptomatic),[2, 3]. Both groups are of great concern as they contribute to the spread of the virus
38 because they are not aware that they are infected. These groups are undetectable through passive
39 surveillance but require instead active surveillance strategy based on massive testing methods. Hence,
40 the need to increase testing capacity entails developing alternative strategies to optimize resources,

1 save time and reduce labor demand, thereby enhancing COVID-19 diagnosis which, in turn, is essential
2 for evaluating the disease spread and for tracing the contacts of infected individuals,[4, 5]. Testing
3 pooled samples by real-time reverse-transcriptase-polymerase chain reaction (rRT-PCR) could be a
4 plausible way to deal with the huge demand for SARS-CoV-2 detection as long as it demonstrates
5 optimum diagnostic performance. This strategy consists of mixing samples in a pool and then
6 performing a single RNA extraction followed by a rRT-PCR assay. If the result is positive, then it must be
7 identified which of the individual samples makes up the pool as positive by performing the RNA
8 extraction and rRT-PCR test for each one of them. On the other side, if the rRT-PCR test is negative it is
9 assumed that all individual samples composing the pool are also negative. Thus, according to this layout
10 it is expected that fewer rRT-PCR tests and extraction reagents will be required instead of analyzing
11 individual samples, leading to save reagents, time and labor demand. This pooling approach was
12 previously developed for the analysis of several infectious diseases, e.g., malaria and HIV,[6, 7] and is
13 currently used as a screening method in blood banks prior to transfusion,[8, 9]. Pooling nasopharyngeal
14 swab samples for RNA virus detection, such as influenza has already been evaluated,[10]. In the case of
15 COVID-19, the method was considered and analyzed as strategy by countries like Germany, Israel and
16 the United States,[11-13] after the Food and Drug Administration (FDA) approved the emergency use of
17 Quest SARS-CoV-2 rRT-PCR test for pooled samples on July, 2020,[14].

18 The aim of this work was the implementation of a multi-sample pool strategy during a specific period of
19 COVID-19 pandemic, in order to decrease costs and response times, while increasing efficiency and
20 testing capacity, thereby contributing to early patient assistance and control of disease spread.

21 **2. Methods**

22 *2.1 Sample pooling*

23 In July 2020, when the background SARS-CoV-2 community prevalence was between 3% and 5% in
24 Córdoba, Argentina,[15] oropharyngeal swab samples in viral transport media (VTM) from testing
25 centers were processed by pooling strategy following the protocol described by Ambrosi et al with
26 minor modifications,[16]. Briefly, from five individual oropharyngeal swab samples, an aliquot of 60 μ L
27 of each was taken to create a pool, with a final volume of 300 μ L. Each pool of samples was processed
28 for RNA extraction and subsequent rRT-PCR analysis. From August 2020 to April 2021, when the
29 community viral prevalence exceeded 5%, oropharyngeal swab samples were collected in 234 closed
30 and semi-closed institutions. Overall, 2314 pools were prepared for testing containing a mix of 5
31 individual samples each from initially 11580 patient samples.

32 *2.2 Nucleic acid extraction and SARS-CoV-2 detection*

33 RNA extraction of the pool was performed using Bioer MagaBio plus Virus DNA/RNA Purification Kit in
34 addition to Bioer GenePure Pro fully automatic Nucleic Abbbcid purification System (Bioer, Hangzhou,
35 China) and EasyPure Viral DNA/RNA Kit (TransGene, Beijin, China), according to the manufacturer's
36 instructions. A multiplex single step real time RT-PCR was carried out for amplification, using DisCoVery
37 SARS-CoV-2 rRT-PCR Detection Kit, which is designed to detect two SARS-CoV-2 target genes: Open
38 Reading Frame 1ab (ORF1ab) and nucleocapsid (N), along with the human ribonuclease P (RNaseP) gene
39 as endogenous control (Safecare Biotech Hangzhou, China).

40 *2.3 Classification criteria*

- 1 - Considering the cycle threshold (Ct) value for ORF1ab and N genes, the pools were classified as:
- 2 Positive: pools with amplification of both genes with $Ct \leq 38$.
- 3 - Negative: those without amplification of both genes, or with fluorescence signal only in one of them
- 4 with $Ct > 40$.
- 5 - Suspected positive or indeterminate: pools that showed amplification in only one gene with $Ct \leq 40$
- 6 and those that amplified both genes with $Ct > 38$.
- 7 To validate the previous results, all tests must amplify the endogenous RNaseP control gene.

8 *2.4 Data processing*

9 Results obtained by Real Time PCR (sample code and their respective Ct) were exported to plain text
10 files from the AriaMx and Linegene software. From these files, the results were organized and
11 interpreted with Perl scripts and conditional rules in Microsoft Excel and then converted into comma-
12 delimited files. These data were incorporated into a database based on APACHE, MYSQL and
13 PHPMYADMIN. A web interface was created to monitor the tests, evaluate coherence through PHP
14 scripts, to visualize the data pools and their disassembly, and to carry out searches.

15 *2.5 Statistical analysis*

16 Differences in Ct values, mean, standard deviation and reduced number of tests were calculated using R
17 version 4.0.5, 2021. The delta Ct value (ΔCt) was defined as the absolute change in Ct value when the
18 pooled sample was tested compared to a positive sample that composed the pool, when it was tested
19 individually. Therefore, a positive ΔCt value (i.e., an increase in Ct value of the pooled sample)
20 represents the loss of rRT-PCR sensitivity as a consequence of individual sample dilution within a pool
21 composed of 5 samples, [17]. ANOVA tests were done to compare groups, and a p-value of 0.05 or less
22 was considered statistically significant.

23 **3. Results**

24 The study included 11570 samples analyzed under 2314 pools format, containing 5 samples each. We
25 found 158 positive (6.8%) and 2024 negative pools (87.5%); 132 were classified as indeterminate (5.7%).
26 Altogether, 290 pools were disassembled (158 classified as positive and 132 suspected to be positive) to
27 analyze each one of the 1450 samples that composed them. As a result, the pooling strategy allowed to
28 save 7806 tests, that is, 67.5% fewer tests were required for the screening, leading to a 3 times
29 reduction in costs.

30 A hundred and five (105) of the positive pools contained a single positive sample, and 53 contained
31 more than one positive sample. Results of Ct variation values comparing each pool and individual
32 samples are shown in Figure 1. We observed that 5-sample pools containing one positive and four
33 negative individual swabs samples, yielded higher Ct values than individual sample testing, exceeded by
34 2.6 cycles on average for both, N and ORF1ab genes (2.6 ± 1.53 cycles for N gene and, 2.6 ± 1.78 for
35 ORF1ab gene). The differences between the Ct value of pooled and individual samples (ΔCt) are
36 illustrated in Figure 2, showing the same mean value and comparable variability for both target genes.
37 For most pools composed by more than one positive individual sample, the Ct values obtained were
38 closer to the average of the individual Ct values, showing a pattern distribution in the middle area of the
39 plot, and decreasing as the number of positive individual swabs increases within the same pool (Figure
40 3).

1 Regarding the 132 indeterminate pools, 19 contained only one positive sample (Table 1), 108 were
2 constituted by all negative individual samples and five contained one suspected positive sample
3 (inconclusive result according to the criteria provided in user manual of the rRT-PCR kit, so a new sample
4 was requested). Analysis of the Ct values distribution of the indeterminate group, indicates that there
5 are no significant differences ($p < 0.05$) for both, N and ORF1ab genes, regardless of the 5-sample pools
6 containing or not positive samples (Figure 4).

7 **4. Conclusions and Discussion**

8 Given the high transmission rates of SARS-CoV-2 and that almost a quarter of infected people are
9 asymptomatic,[2, 3] one of the best strategies to control the virus spread is the early detection of those
10 infected and their subsequent isolation. To achieve early detection of the infection, it is necessary to
11 carry out active surveillance and massive testing. In this sense, different experimental or computational
12 modeling tests have been carried out at the laboratory level to study the sensitivity and accuracy of the
13 SARS-CoV2 detection strategies using different grouping techniques. However, at present there are very
14 few studies reporting results of some of these strategies applied in a real setting, demonstrating their
15 applicability on a large scale with patient samples.

16 This study demonstrates that the strategy based on the analysis of samples in a format of pools,
17 composed of 5 samples each, is a reliable approach for an efficient screening of SARS-CoV-2 testing in a
18 context of pandemics. In addition, it contributes to save costs of molecular diagnosis and labor demand
19 of the health personnel in areas or institutions with low viral circulation. It can be useful to monitor the
20 infection rate in closed or semi-closed establishments such as residential homes, police and military
21 headquarters, prisons or hospitals, due to these places being populated by persons who are generally in
22 close contact and/or with risk factors,[16].

23 It is important to highlight that optimum size pool must be determined according to the prevalence in
24 the area under study,[4, 18]. Previous studies have analyzed different pool sizes, from 2- to 64-
25 samples,[16, 19] and agreed that the number of samples in the pool is inversely proportional to the test
26 sensitivity,[20, 21]. It has been reported that SARS-CoV-2 prevalence is a suitable criterion to define the
27 most efficient pool size, defining 5-sample groups as appropriate when the prevalence rates are about
28 5%,[4, 16].

29 According to our findings, as well as previous reports, pooling samples entails the loss of sensitivity and
30 an increase of the Ct value of pools compared with the individual specimen due to the sample dilution,
31 affecting especially detection of samples with low viral loads,[20-22]. The increase in the Ct value
32 observed in our study (2.6 cycles on average) for both target genes was comparable to those reported in
33 other studies of SARS-CoV-2 testing in pools constituted by 5 individual samples, where ΔCt ranges were
34 between 2 and 3.4,[16, 20, 23, 24]. This variation results in more indeterminate tests than would be
35 obtained in a single sample approach, mainly in those groups that contained individual positive samples
36 with a Ct value close to 38. In both positive and indeterminate pools, the Ct value distribution for the N
37 and the ORF1ab genes shows the same trend observed in individual samples: lower Ct values were
38 detected for the N gene than for the ORF1ab target sequence.

39 Almost every suspected positive or indeterminate pool was classified in that way because only the N
40 gene showed amplification, which could be due to a more sensitivity of this gene, contrasting with
41 ORF1ab gene,[25]. Although in this indeterminate group we found only 19 pools (14.4%) that contained
42 positive samples, the mean and range of the Ct values of both, N and ORF1ab genes, were similar to

1 those found for the remaining pools. Hence, it was not possible to establish a more rigorous cut-off Ct
2 value to avoid disarming groups composed of samples that will ultimately be all negative. Therefore, it
3 was mandatory to disassemble all indeterminate groups to avoid false-negative results. However, this
4 approach allowed the correct identification of 99.8 % of samples as positive (7,6%) or negative (92,2%),
5 without the necessity to perform 7,806 tests, thus, saving 67,5% of costs and decreasing personnel labor
6 demanding.

7 The pooling approach allows to deal with a variety of difficulties associated with a context of pandemics,
8 most notably the limited availability of reagents, supplies, equipment and high labor demand of
9 laboratory workers, as well as the high cost. However, the decision to implement this strategy must
10 consider the total testing capacity and the disease prevalence in a specific geographic area. The
11 limitation of this strategy to test the internal control of each sample, which is required to control the
12 specimen quality, must also be underlined. So, false-negative results may occur if samples are
13 improperly collected, transported, or handled. Hence, negative results obtained by pooled sampling do
14 not preclude SARS-CoV-2 infection and should not be used as the only criteria for treatment or for other
15 social management decisions.

16 The high sensitivity of rRT-PCR assays makes pool testing an efficient system that can be applied for
17 resource optimization when positivity rate is low (e.g., 5% or lower), improving laboratory testing
18 capacities without additional requirements in terms of equipment availability or qualified personnel,[19,
19 21, 26].

20 Our results show that the implementation of the strategy of pooling was able to save 67,5% of rRT-PCR
21 reactions in a low viral circulation scenario. The approach of testing in pools was a positive experience
22 that allow expanding sample processing capabilities allowing massive testing and early outbreak
23 detections. Our findings could be taken into account as a strategy to be implemented in a new post-
24 pandemic scenario, with an expected decrease of viral circulation (due to vaccine programs) to carry out
25 large-scale testing in hospitals, care homes, schools, and other closed and semi-closed institutions.

26 **Ethics**

27 The Government of the Province of Córdoba through the Ministry of Health determined that the ethical
28 review, approval and written informed consent are not required for the study of oropharyngeal swab
29 samples obtained from human participants in the study “SARS-CoV-2 detection in multi-sample pools in
30 a real pandemic scenario: a screening strategy of choice for active surveillance” in accordance with local
31 legislation and institutional requirements. The Government of the Province of Córdoba gives the ethical
32 review of the SARS-CoV-2 detection in multi-sample pools during 2020 and 2021 under strict
33 confidentiality rules, based on the need for rapid surveillance and availability of methodologies for
34 diagnosis of COVID-19.

35 **Acknowledgments**

36 The authors would like to acknowledge health care workers who take and processed the samples, all the
37 staff of CEPROCOR laboratory and the team from Facultad de Ciencias Químicas, Universidad Nacional
38 de Córdoba for their invaluable work and compromised attitude in favor of the community throughout
39 the SARS-CoV-2 pandemic.

40 **Conflict of interests**

41 The authors declare no conflict of interest.

1 **Author contributions**

2 Conceptualization: AMC, MBP, VR and GC.

3 Methodology: AMC, PV, GGM, JRD, FC, JG, AM, CC, LRC, GDC, MBP, VR and AB.

4 Investigation: AMC, PV, GGM, JRD, FC, JG, AM, CC, LRC, GDC, FCQG, PS, MBP, VR, AB and GC.

5 Resources: MGB, LL and GC

6 Formal analysis: AMC, GDC, PV, JLB, MBP, VR and AB.

7 Writing - Original Draft: AMC and GDC.

8 Writing - Review & Editing: AMC, GDC, PV, AB, MBP, JLB and VR.

9 Visualization: AMC, MBP and VR.

10 Data Curation: AMC, PV, GDC, AB, LL, JLB, MGB and GC

11 Supervision: AMC, MBP, JLB and VR.

12 Funding acquisition: LL and MGB.

13 All authors contributed on the article and approved the submitted version.

14 **Funding**

15 This study was part of the active surveillance for SARS-CoV-2 dissemination carried out by the Ministry
16 of Health of the Province of Córdoba, Argentina. The funders had no role in study design, data collection
17 and analysis, decision to publish or preparation of the manuscript. This research did not receive any
18 specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

19

1 References

- 2 1. Grant, M.C., et al., *The prevalence of symptoms in 24,410 adults infected by the novel*
3 *coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from*
4 *9 countries*. PLoS One, 2020. **15**(6): p. e0234765.
- 5 2. Alene, M., et al., *Magnitude of asymptomatic COVID-19 cases throughout the course of*
6 *infection: A systematic review and meta-analysis*. PLoS One, 2021. **16**(3): p. e0249090.
- 7 3. Syangtan, G., et al., *Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis*.
8 Front Public Health, 2020. **8**: p. 587374.
- 9 4. Abdalhamid, B., et al., *Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing*
10 *Resources*. Am J Clin Pathol, 2020. **153**(6): p. 715-718.
- 11 5. Alcoba-Florez, J., et al., *Increasing SARS-CoV-2 RT-qPCR testing capacity by sample pooling*. Int J
12 Infect Dis, 2021. **103**: p. 19-22.
- 13 6. Bharti, A.R., et al., *Malaria diagnosis by a polymerase chain reaction-based assay using a pooling*
14 *strategy*. Am J Trop Med Hyg, 2009. **81**(5): p. 754-7.
- 15 7. van Zyl, G.U., et al., *Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a*
16 *resource-limited setting*. Clin Infect Dis, 2011. **52**(2): p. 264-70.
- 17 8. Dwyre, D.M., L.P. Fernando, and P.V. Holland, *Hepatitis B, hepatitis C and HIV transfusion-*
18 *transmitted infections in the 21st century*. Vox Sang, 2011. **100**(1): p. 92-8.
- 19 9. Garcia, Z., et al., *Evaluation of a pooling method for routine anti-HCV screening of blood donors*
20 *to lower the cost burden on blood banks in countries under development*. J Med Virol, 1996.
21 **49**(3): p. 218-22.
- 22 10. Van, T.T., et al., *Pooling nasopharyngeal/throat swab specimens to increase testing capacity for*
23 *influenza viruses by PCR*. J Clin Microbiol, 2012. **50**(3): p. 891-6.
- 24 11. Hogan, C.A., M.K. Sahoo, and B.A. Pinsky, *Sample Pooling as a Strategy to Detect Community*
25 *Transmission of SARS-CoV-2*. JAMA, 2020. **323**(19): p. 1967-1969.
- 26 12. Lohse, S., et al., *Pooling of samples for testing for SARS-CoV-2 in asymptomatic people*. Lancet
27 Infect Dis, 2020. **20**(11): p. 1231-1232.
- 28 13. Yelin, I., et al., *Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools*. Clin Infect Dis, 2020.
29 **71**(16): p. 2073-2078.
- 30 14. FDA, U.S., *Coronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample*
31 *Pooling in Diagnostic Testing*. 2020, Food & Drug Administration.
- 32 15. Córdoba, G.d.l.p.d., *Informe diario de casos y medidas*. 2021.
- 33 16. Ambrosis, N., et al., *Active Surveillance of Asymptomatic, Presymptomatic, and*
34 *Oligosymptomatic SARS-CoV-2-Infected Individuals in Communities Inhabiting Closed or Semi-*
35 *closed Institutions*. Front Med (Lausanne), 2021. **8**: p. 640688.
- 36 17. Chong, B.S.W., et al., *Sample pooling is a viable strategy for SARS-CoV-2 detection in low-*
37 *prevalence settings*. Pathology, 2020. **52**(7): p. 796-800.
- 38 18. Regen, F., et al., *A simple approach to optimum pool size for pooled SARS-CoV-2 testing*. Int J
39 Infect Dis, 2020. **100**: p. 324-326.
- 40 19. Sunjaya, A.F. and A.P. Sunjaya, *Pooled Testing for Expanding COVID-19 Mass Surveillance*.
41 Disaster Med Public Health Prep, 2020. **14**(3): p. e42-e43.
- 42 20. Prahara, I., et al., *Pooled testing for COVID-19 diagnosis by real-time RT-PCR: A multi-site*
43 *comparative evaluation of 5- & 10-sample pooling*. Indian J Med Res, 2020. **152**(1 & 2): p. 88-94.
- 44 21. Torres, I., E. Albert, and D. Navarro, *Pooling of nasopharyngeal swab specimens for SARS-CoV-2*
45 *detection by RT-PCR*. J Med Virol, 2020. **92**(11): p. 2306-2307.
- 46 22. Mahmoud, S.A., et al., *Evaluation of pooling of samples for testing SARS-CoV- 2 for mass*
47 *screening of COVID-19*. BMC Infect Dis, 2021. **21**(1): p. 360.

- 1 23. Cabrera Alvargonzalez, J.J., et al., *Pooling for SARS-CoV-2 control in care institutions*. BMC Infect
2 Dis, 2020. **20**(1): p. 745.
3 24. Farfan, M.J., et al., *Optimizing RT-PCR detection of SARS-CoV-2 for developing countries using*
4 *pool testing*. Rev Chilena Infectol, 2020. **37**(3): p. 276-280.
5 25. Zhou, Y., et al., *Sensitivity evaluation of 2019 novel coronavirus (SARS-CoV-2) RT-PCR detection*
6 *kits and strategy to reduce false negative*. PLoS One, 2020. **15**(11): p. e0241469.
7 26. de Salazar, A., et al., *Sample pooling for SARS-CoV-2 RT-PCR screening*. Clin Microbiol Infect,
8 2020. **26**(12): p. 1687 e1-1687 e5.

9

10 **Table 1.** Ct values of positive individual samples from 19 indeterminate pools.

N gene		ORF1ab gene	
Pooled (Ct)	Individual Sample (Ct)	Pooled (Ct)	Individual Sample (Ct)
37.4	33.7	NA	36.1
35.7	34.6	NA	36.6
NA	37.9	38.3	36.7
32.9	29.6	39.9	31.7
35.2	33.0	41.0	35.0
37.0	33.5	NA	36.6
38.9	34.4	NA	36.5
36.3	32.7	NA	34.7
35.5	31.2	NA	36.2
37.3	32.1	NA	36.0
36.9	34.7	NA	37.7
34.6	31.1	38.4	32.9
NA	36.0	39.5	37.8
37.2	35.4	NA	37.5
39.9	36.4	NA	37.0
38.0	31.9	NA	34.4
35.8	32.7	NA	35.3
38.6	31.0	NA	33.5
NA	36.5	39.5	35.3

11 NA: no amplification

12


13

14


15

16

17




1
2 Figure 1. **Pools with a single positive.** Scatter plots showing cycle threshold (Ct) values and Ct shifts
3 detected by rRT-PCR in five-samples pools (squares), composed of four negative and one positive
4 samples, with respect to the individual positive samples (circles) for N (top graph) and ORF1ab (bottom
5 graph) genes. (2 column image)




1

2 Figure 2. **Ct value shift due to sample pooling.** Box plot showing the difference between the Ct values
3 (Δ Ct) of five-samples pools (composed of 1 positive and 4 negative samples) and the respective
4 individual positive samples for N and ORF1ab target genes. (1.5 column image)



5

1 Figure 3. **Pools with two or more positives.** Scatter plots showing Ct values detected by rRT-PCR in five-
2 samples pools (squares) and the individual positive samples (circles) from pools containing 2 (Pool # 1-
3 27), 3 (Pool # 28-37), 4 (Pool # 38-47) or 5 (Pool # 39-53) positive samples. The analysis was performed
4 for N (top graph) and ORF1ab (bottom graph) genes. (2 column image)



5
6 Figure 4. **Pools classified as indeterminate.** Box plot showing Ct values of N and ORF1ab genes from
7 indeterminate pools which were finally classified as pools constituted by all negative samples(left), pools
8 containing one positive sample (middle) and the individual positive samples after deconvolution (right).
9 (2 column image)

10